AbbVie (ABBV) News Today → What’s Really Next for America… (From Porter & Company) (Ad) Free ABBV Stock Alerts $166.42 +2.07 (+1.26%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 2:00 PM | marketbeat.comGreat Lakes Advisors LLC Lowers Stock Position in AbbVie Inc. (NYSE:ABBV)Great Lakes Advisors LLC cut its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 20.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 697,203 shares of the company's stock after selling 179,May 18 at 12:22 AM | marketbeat.comAbbVie Inc. (NYSE:ABBV) Shares Sold by Princeton Capital Management LLCPrinceton Capital Management LLC decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 68.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,267 shares of the company's stock aftMay 17 at 11:56 PM | msn.comCantor Fitzgerald Initiates Coverage of AbbVie (ABBV) with Overweight RecommendationMay 17 at 6:55 PM | msn.comAbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': AnalystMay 17 at 2:48 PM | marketbeat.comAbbVie (NYSE:ABBV) Trading 0.5% Higher AbbVie (NYSE:ABBV) Trading 0.5% HigherMay 17 at 1:54 PM | markets.businessinsider.comThe Analyst Verdict: AbbVie In The Eyes Of 5 ExpertsMay 17 at 8:01 AM | marketbeat.comAbbVie (NYSE:ABBV) Coverage Initiated at Cantor FitzgeraldCantor Fitzgerald began coverage on AbbVie in a research report on Friday. They issued an "overweight" rating and a $200.00 price objective for the company.May 17 at 7:30 AM | prnewswire.comAbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®May 17 at 7:11 AM | investorplace.com7 Value Stocks to Buy and Hold for a Decade of DominanceMay 17 at 7:08 AM | marketbeat.comAbbVie Q1 Earnings TranscriptMay 17 at 4:30 AM | americanbankingnews.comZacks Research Weighs in on AbbVie Inc.'s FY2024 Earnings (NYSE:ABBV)May 16 at 4:42 PM | marketbeat.comAbbVie (NYSE:ABBV) Stock Price Down 0.8%AbbVie (NYSE:ABBV) Stock Price Down 0.8%May 16 at 2:56 PM | marketbeat.comAbbVie Inc. (NYSE:ABBV) Short Interest UpdateAbbVie Inc. (NYSE:ABBV - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 14,480,000 shares, an increase of 6.9% from the April 15th total of 13,540,000 shares. Based on an average daily volume of 5,670,000 shares, the short-interest ratio is presently 2.6 days. Approximately 0.8% of the shares of the company are sold short.May 16 at 10:48 AM | msn.comAbbVie makes psychedelic play with $2bn Gilgamesh collaborationMay 16 at 8:38 AM | marketbeat.comFY2024 EPS Estimates for AbbVie Inc. Lifted by Analyst (NYSE:ABBV)AbbVie Inc. (NYSE:ABBV - Free Report) - Research analysts at Zacks Research increased their FY2024 earnings per share (EPS) estimates for AbbVie in a note issued to investors on Tuesday, May 14th. Zacks Research analyst S. Ganoria now anticipates that the company will post earnings of $11.21 perMay 16 at 6:00 AM | investorplace.comWall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for May 2024May 16 at 2:42 AM | americanbankingnews.comAbbVie Inc. (NYSE:ABBV) to Post Q2 2024 Earnings of $3.01 Per Share, Zacks Research ForecastsMay 15 at 11:53 PM | marketbeat.comAbbVie Inc. (NYSE:ABBV) Shares Sold by Janney Capital Management LLCJanney Capital Management LLC trimmed its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 17.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 119,062 shares of the company's stock after selling 24,946 shares duMay 15 at 8:11 PM | marketbeat.comAbbVie (NYSE:ABBV) Stock Price Up 0.9%AbbVie (NYSE:ABBV) Stock Price Up 0.9%May 15 at 6:24 PM | benzinga.comUnpacking the Latest Options Trading Trends in AbbVieMay 15 at 5:50 PM | seekingalpha.comAbbVie, Inc. (ABBV) Bank of America Health Care Conference Call TranscriptMay 15 at 7:49 AM | marketbeat.comZacks Research Research Analysts Lift Earnings Estimates for AbbVie Inc. (NYSE:ABBV)AbbVie Inc. (NYSE:ABBV - Free Report) - Zacks Research upped their Q2 2024 earnings per share (EPS) estimates for AbbVie in a research report issued on Tuesday, May 14th. Zacks Research analyst S. Ganoria now expects that the company will earn $3.01 per share for the quarter, up from their previoMay 15 at 12:47 AM | marketbeat.comMinichMacGregor Wealth Management LLC Has $246,000 Holdings in AbbVie Inc. (NYSE:ABBV)MinichMacGregor Wealth Management LLC decreased its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 94.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,586 shares of the company's stock after selling 24,656 shMay 14, 2024 | marketbeat.comAbbVie (NYSE:ABBV) Shares Down 0.2% AbbVie (NYSE:ABBV) Shares Down 0.2%May 14, 2024 | businesswire.comAlzamend Neuro Announces Initial Closing of Private PlacementMay 14, 2024 | fool.com3 Magnificent Stocks That Are Passive Income MachinesMay 13, 2024 | marketbeat.comBoston Partners Decreases Stock Holdings in AbbVie Inc. (NYSE:ABBV)Boston Partners reduced its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 7.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,202,814 shares of the company's stock after selling 93,821 shares durinMay 13, 2024 | markets.businessinsider.comAbbVie To Collaborate With Gilgamesh To Develop Next-Gen Psychiatric TherapiesMay 13, 2024 | msn.comAbbVie, Gilgamesh to develop next-generation psychedelic drugsMay 13, 2024 | marketbeat.comAbbVie (NYSE:ABBV) Trading Up 0.7%AbbVie (NYSE:ABBV) Trading 0.7% HigherMay 13, 2024 | fool.comWhat Is the Dividend Payout for AbbVie Stock?May 13, 2024 | prnewswire.comAbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric DisordersMay 12, 2024 | marketbeat.comKing Wealth Management Group Purchases 5,038 Shares of AbbVie Inc. (NYSE:ABBV)King Wealth Management Group grew its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 189.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,701 shares of the company's stock after purchasingMay 12, 2024 | americanbankingnews.comAbbVie (NYSE:ABBV) Trading Up 0.1%May 11, 2024 | marketbeat.comSP Asset Management LLC Has $35.58 Million Stake in AbbVie Inc. (NYSE:ABBV)SP Asset Management LLC grew its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 3.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 229,563 shares of the company's stock after acquiring an additioMay 11, 2024 | businesswire.comLANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPMay 11, 2024 | fool.comWant Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.May 10, 2024 | marketbeat.comAbbVie (NYSE:ABBV) Shares Up 0.1%AbbVie (NYSE:ABBV) Stock Price Up 0.1%May 10, 2024 | marketbeat.comUS Asset Management LLC Takes $1.05 Million Position in AbbVie Inc. (NYSE:ABBV)US Asset Management LLC purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,744 shares of the company's stock, valued at appMay 10, 2024 | fool.com3 Rock-Solid Dividend Stocks That Are Ideal for RetireesMay 9, 2024 | marketbeat.comBreed s Hill Capital LLC Invests $1.18 Million in AbbVie Inc. (NYSE:ABBV)Breed s Hill Capital LLC purchased a new position in AbbVie Inc. (NYSE:ABBV - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 7,642 shares of the company's stock, valued at apprMay 9, 2024 | marketbeat.comAbbVie (NYSE:ABBV) Stock Price Up 0.5%AbbVie (NYSE:ABBV) Stock Price Up 0.5%May 9, 2024 | finance.yahoo.comQ1 2024 Regenxbio Inc Earnings CallMay 8, 2024 | marketbeat.comEverpar Advisors LLC Takes $946,000 Position in AbbVie Inc. (NYSE:ABBV)Everpar Advisors LLC purchased a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 6,107 shares of the company's stock, valued at approximaMay 8, 2024 | markets.businessinsider.comAbbVie's Qulipta Gets Health Canada Approval For Chronic Migraine In AdultsMay 8, 2024 | marketbeat.comAbbVie (NYSE:ABBV) Shares Down 1.4% AbbVie (NYSE:ABBV) Stock Price Down 1.4%May 8, 2024 | investing.comAbbVie Stock Poised for New All-Time Highs in 2024May 8, 2024 | marketbeat.comCullen Frost Bankers Inc. Has $55.74 Million Stock Position in AbbVie Inc. (NYSE:ABBV)Cullen Frost Bankers Inc. raised its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 10.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 359,704 shares of the company's stock after buyiMay 7, 2024 | marketbeat.comAbbVie (NYSE:ABBV) Stock Price Up 0%AbbVie (NYSE:ABBV) Trading Up 0%May 7, 2024 | investorplace.comBiotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare Get AbbVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter. Email Address [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. ABBV Media Mentions By Week ABBV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABBV News Sentiment▼0.610.49▲Average Medical News Sentiment ABBV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABBV Articles This Week▼4323▲ABBV Articles Average Week Get AbbVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MRK News Today JNJ News Today PFE News Today BMY News Today ZTS News Today MRNA News Today SGEN News Today IQV News Today IDXX News Today BNTX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ABBV) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceI’m afraid WWIII is a very real possibility Porter & CompanyProtect Your Bank Account Before It’s Too LateWeiss RatingsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
